A Cluster-Randomized Trial to Assess the Efficacy of Targeting Trachoma Treatment to Children. by Amza, Abdou et al.
Amza, A; Kadri, B; Nassirou, B; Cotter, SY; Stoller, NE; Zhou,
Z; Bailey, RL; Mabey, DC; Porco, TC; Keenan, JD; Gaynor, BD;
West, SK; Lietman, TM (2017) A cluster-randomized trial to assess
the efficacy of targeting trachoma treatment to children. Clinical
infectious diseases , 64 (6). pp. 743-750. ISSN 1058-4838 DOI:
10.1093/cid/ciw810
Downloaded from: http://researchonline.lshtm.ac.uk/3225427/
DOI: 10.1093/cid/ciw810
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the author(s)
Clinical Infectious Diseases
Herd Effect for Trachoma • CID 2017:64 (15 March) • 743
Clinical Infectious Diseases®  2017;64(6):743–50
A Cluster-Randomized Trial to Assess the Efficacy of 
Targeting Trachoma Treatment to Children
Abdou Amza,1 Boubacar Kadri,1 Beido Nassirou,1 Sun Y. Cotter,2 Nicole E. Stoller,2 Zhaoxia Zhou,2 Robin L. Bailey,3 David C. Mabey,3  
Travis C. Porco,2,4,5 Jeremy D. Keenan,2,4 Bruce D. Gaynor,2,4 Sheila K. West,6 and Thomas M. Lietman2,4,5
1Programme FSS/Université Abdou Moumouni de Niamey, Programme National de Santé Oculaire, Niamey, Niger; 2F.I. Proctor Foundation, University of California, San Francisco; 3Clinical 
Research Unit, Department of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom; Departments of 4Ophthalmology and 5Epidemiology and 
Biostatistics, University of California, San Francisco; and 6Dana Center for Preventive Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland
Background. The World Health Organization recommends annual treatment of entire trachoma-endemic communities, 
although children typically have a higher load, longer duration, and greater likelihood of infection.
Methods. Forty-eight communities in Matameye, Niger, were randomized to annual oral azithromycin treatment of the entire 
community or biannual treatment of children aged 0–12 years only. Both children and adults were monitored for ocular chlamydial 
infection by polymerase chain reaction.
Results. The prevalence of childhood infection was reduced in the annually treated arm from 21.2% (95% confidence inter-
val [CI], 15.2%–28.0%) at baseline to 5.8% (95% CI, 3.2%–9.0%) at 36 months (P < .001) and in the biannual arm from 20.2% 
(95% CI, 15.5%–25.3%) to 3.8% (95% CI, 2.2%–6.0%; P < .001). Adult infection in the annual arm was reduced from 1.7% (95% 
CI, .9%–2.7%) to 0.3% (95% CI, .0%–.7%) and in the biannual arm from 1.2% (95% CI, .5%–2.2%) to 0.0% (95% CI, .0%–.7%; 
P = .005). The effect of biannual treatment of children compared with annual treatment of the entire community in both children 
(95% CI, –.04% to .02%) and adults (95% CI, .9%–2.7%) excluded the prespecified noninferiority threshold of 6% (P = .003 and 
P < .001, respectively).
Conclusions. Periodic distribution of antibiotics to children in trachoma-endemic communities reduces chlamydial infection in 
both children and untreated adults, suggesting a form of herd protection. Biannual treatment of children was comparable to (specif-
ically, noninferior to) annual treatment of the entire community, and may offer lower antibiotic use and other logistical advantages.
Clinical Trials Registration. NCT00792922.
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Trachoma-control programs distribute oral azithromycin to 
treat the ocular strains of chlamydia that cause the blinding 
disease [1]. As it is difficult, or even impossible, to precisely 
determine which individuals are infected, the World Health 
Organization (WHO) recommends treating the entire 
community when >10% of children have clinical signs of 
trachoma. In most settings, the prevalence is highest in chil-
dren, and the majority of adults do not harbor chlamydia [2]. 
Mathematical models suggest that children could form a core 
group for the transmission of infection—that is, infection 
would not persist indefinitely in the community if children 
were effectively removed from transmission by vaccination 
or periodic antibiotics [3–5]. Recent empirical studies have 
shown that periodic mass treatment of children can reduce 
the prevalence of infection in adults who were not treated, at 
least over the course of a year [6]. If children do form a core 
group for transmission, then programs of longer duration 
might progressively reduce and eliminate infection, even in 
untreated adults.
Antibiotic distributions can cause adverse events, select 
for antibiotic resistance, and consume valuable resources. 
Gastrointestinal side effects are common, but typically mild. 
No azithromycin-resistant chlamydia has yet been docu-
mented in trachoma programs [7–10], although mass azith-
romycin distributions do select for macrolide-resistant strains 
of pneumococcus. Mathematical models have estimated that 
in moderately affected areas, treating children twice per year 
could eliminate infection, and empirical studies have sug-
gested this may reduce costs [11]. Reducing the proportion 
of the community that receives treatment could be justified if 
similar control of trachoma could be obtained. Here, we assess 
whether the prevalence of ocular chlamydial infection in 
adults decreases when children alone are periodically treated 
with oral azithromycin, and compare this to the current WHO 
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recommendation of annual treatment of the entire commu-
nity for 3 years. As trachoma programs target the community 
rather than the individual, we randomize intervention at the 
community level.
METHODS
Study Setting and Design
The Partnership for the Rapid Elimination of Trachoma 
(PRET) was a set of cluster-randomized clinical trials in 
Tanzania, The Gambia, and Niger (ClinicalTrials.gov identi-
fier NCT00792922) [12–14]. From May 2010 to August 2013, 
the Niger trial enrolled participants in the Matameye District, 
Zinder Region, Niger. Forty-eight grappes (smallest govern-
ment health unit) from 6 Centres de Santé Intégrées (CSIs) 
were included; in this manuscript each grappe is termed a 
community.
Community Randomization
Communities were eligible for the study if they had a popu-
lation between 250 and 600 at the most recent government 
census (72 of 235 communities in the Zinder Region). Prior 
to mass antibiotic treatment, a door-to-door census was con-
ducted in 8 communities per CSI. A random sample of 100 
children aged 0–60 months was drawn from the census and 
assessed for active trachoma according to the WHO simpli-
fied grading system (trachomatous inflammation–follicu-
lar [TF] and/or trachomatous inflammation–intense [TI]) 
[15, 16]. Communities with <10% prevalence of active tra-
choma among sampled children were excluded, in which case 
another community from the CSI was censused and moni-
tored for trachoma until each CSI had 8 enrolled communi-
ties [16]. To account for community-level predictors in study 
arms, we utilized stratified blocked randomization of com-
munities within each CSI by high or low clinical trachoma 
prevalence in children. Communities within a CSI were 
ranked by clinical trachoma among children; those above the 
median were designated high prevalence and those below, 
low prevalence. Communities were randomized in a 2 ×  2 
factorial design to assess the effects of (1) standard (~80%) 
and enhanced (>90%) coverage, and (2) annual treatment of 
all ages vs biannual treatment of individuals aged ≤12 years. 
Individuals were randomly selected for trachoma monitoring 
[15]. One author (T. C. P.) used the statistical package R (ver-
sion 2.12; R Foundation for Statistical Computing, Vienna, 
Austria; www.r-project.org) to generate the random alloca-
tion sequence of communities [15].
Communities randomized to annual treatment received 3 
rounds of mass azithromycin treatment, whereas those ran-
domized to biannual treatment received 6 rounds. In annu-
ally treated communities, study participants aged ≥6 months 
received a directly observed dose of oral azithromycin 
(20 mg/kg up to a maximum dose of 1 g in adults). In bian-
nually treated communities, only study participants aged 
6 months to 12 years were offered treatment. In all commu-
nities, children <6  months of age were offered topical tet-
racycline ointment (1%) to be applied to both eyes twice a 
day for 6 weeks. Pregnant women (annual arm) and those 
allergic to macrolides (both arms) were also offered topical 
tetracycline.
Clinical and Laboratory Assessments
Communities were censused annually. From the most recent 
PRET study census for trachoma monitoring, we randomly 
selected 100 children aged 0–5 years (or all children if <100) 
and 40 individuals aged ≥15 years. Children were examined 
according to the WHO simplified grading system as previ-
ously described [15, 16]. The right and left upper tarsal con-
junctiva was everted and the right conjunctiva was swabbed 
for the presence of chlamydial DNA. In both arms, childhood 
examinations and swabs were biannual, while adult swabs 
were at baseline, 6, 12, and 36 months by design. Swabs were 
collected without media and transported to the University of 
California, San Francisco (UCSF) and stored at –80°. Swabs 
were pooled within a community and age group into pools of 5 
plus a remainder pool. The pool was processed for chlamydia 
with Amplicor polymerase chain reaction (PCR) testing (F. 
Hoffmann-La Roche AG, Basel), and the prevalence of infec-
tion estimated from the pooled results as described previously 
[17]. In communities where >80% of pools were positive, all 
samples were then processed individually for a more accurate 
community prevalence.
Statistical Methods
Both arms showed very few events (infections) for adults at 
all time points and children posttreatment. Our prespecified 
analytic plan mandated adjusting for baseline prevalence, 
and using the square root transformed prevalence (due to the 
relatively heavy tail expected, with many communities hav-
ing low or no infection and occasional communities having 
considerably more infection). A noninferiority margin of 6% 
was prespecified; we fail to find evidence of noninferiority if 
the confidence interval (CI) includes values ≥6% in difference. 
Given the binary outcome variable, we used a Monte Carlo 
version of the shift-alternative procedure. In this procedure, 
we add additional cases to the treatment arm with a specified 
probability, and conduct the hypothesis test on this augmented 
data set [18]. As more and more cases are added to the treat-
ment arm, rejection of the null hypothesis becomes more and 
more likely. Similarly, we added additional cases to the control 
arm and repeated the procedure. We approximated the shift 
in each direction needed to reject the null hypothesis with an 
expected P value of .025 (for a total α of .05). The analysis 
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was conducted at the community level using the square root 
of the prevalence, including as covariates baseline prevalence, 
an indicator for enhanced vs standard coverage, and an indi-
cator for frequency and targeting (children every 6 months vs 
community every year).
We estimated that 48 communities (24 communities per 
arm) would provide >80% power to detect an absolute differ-
ence of 6% in the prevalence of infection in children, assum-
ing a standard deviation in the community-level prevalence of 
5%. The primary analysis was a comparison of the prevalence 
of chlamydia in children between the 2 arms. Other prespeci-
fied outcomes include comparison of the prevalence of infec-
tion in adults between the 2 arms and between baseline and 
36-month visits.
Data and Safety Monitoring Committee
Although no formal efficacy or futility stopping rules were pre-
specified in this trial, a data and safety monitoring committee 
met annually to review results and serious adverse events.
Ethics Statement
We acquired ethical approval from the UCSF Committee 
for Human Research and the Comité d’Ethique du Niger 
(Ethical Committee of Niger). This study was registered at 
ClinicalTrials.gov (NCT00792922) and implemented in 
accordance with the Declaration of Helsinki. Given the high 
rates of illiteracy in the study area, both institutional review 
boards approved the obtaining of verbal consent from each 
local community chief before randomization and verbal con-
sent of each individual’s or guardian’s consent prior to the 
examination.
RESULTS
The 24 annually treated communities had a mean number of 
136 children (range, 59–485) aged 0–12 years and the 24 bian-
nually treated communities had a mean of 146 children (range, 
44–580) (Figure  1). Age and sex of children examined were 
similar between arms at baseline, as were the prevalence of 
clinical activity and infection (Table 1). The antibiotic coverage 
obtained at each visit is displayed for children aged 0–12 years 
and adults >12 years (Table 2).
Childhood infection was reduced in the annually treated 
arm from 21.2% (95% confidence interval [CI], 15.2%–
28.0%) at baseline to 5.8% (95% CI, 3.2%–9.0%) at 36 months 
(P < .001), and in the biannually treated arm from 20.2% (95% 
CI, 15.5%–25.3%) to 3.8% (95% CI, 2.2%–6.0%; P  <  .001) 
(Figure 2A and 2B). Note that the majority of any impact on 
infection occurred after the first treatment. After adjusting for 
infection at baseline, ocular chlamydial infection at 36 months 
was 0.2% higher in the biannually treated group than the 
annually treated group (95% CI, 4.0% lower to 2.0% higher); 
the 6% noninferiority threshold could be excluded (P = .003). 
Adult infection in the annually treated arm was reduced from 
1.7% (95% CI, .9%–2.7%) to 0.3% (95% CI, .0%–.7%; P < .001) 
and in the biannually treated arm from 1.2% (95% CI, .5%–
2.2%) to 0.0% (95% CI, .0%–.7%; P  =  .005) (Figure  3A and 
3B). The difference between the arms was not significant (95% 
CI, –.02% to .03%), and the 6% noninferiority threshold could 
be excluded (P < .001).
Childhood clinical activity (TF) was reduced in the annu-
ally treated arm from 27.7% (22.0%–34.1%) at baseline to 8.0% 
(5.0%–11.6%) at 36 months (P <  .001), and in the biannually 
treated arm from 24.3% (20.0%–29.7%) to 7.8% (5.3%–11.4%; 
P  <  .001) (Figure  4A and 4B). No significant difference was 
found between the 2 arms at 36 months (P = .67).
DISCUSSION
Biannual treatment of children aged ≤12 years achieved simi-
lar results to the WHO-recommended annual treatment of all 
individuals in the community. The prevalence of infection in 
children was reduced >4-fold over 36 months in both bian-
nually and annually treated communities. At 36 months, we 
were unable to identify infection in adults in the biannually 
treated communities, even though the adults themselves were 
not treated. The low baseline prevalence of infection identi-
fied in adults (1.2%) and the significantly lower prevalence 
(0.0%) at 36 months suggests that excellent results are possi-
ble even without treating adults, at least in areas with a sim-
ilar baseline prevalence of trachoma. Treating children can 
often be logistically easier than treating adults, as children 
are typically at home or in school during distribution hours. 
Thus, targeting children may be an attractive alternative to 
programs wishing to conserve resources while achieving sim-
ilar results [11].
Mathematical models have suggested that complete elimina-
tion can be achieved with periodic antibiotic treatment, even 
with an imperfect antibiotic and incomplete coverage of the 
community with an imperfect antibiotic [3]. Previous empir-
ical studies conducted in severely affected communities have 
confirmed this [19, 20]. In 2 different studies, infants aged 
<1 year had a significant decrease in ocular chlamydial infec-
tion, though they themselves had not received treatment [21, 
22]. In several other communities, elimination of infection was 
achieved with imperfect coverage [19, 20, 23]. Taken together, 
these lines of evidence suggest that targeting treatment to a rel-
atively small core group most likely to be infected is an effective 
strategy for reducing ocular chlamydial infection in the entire 
community.
This study demonstrated a reduction in ocular chlamydia 
among untreated individuals of the biannually treated group, 
supporting the hypothesis that repeated mass azithromycin 
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distributions offer a form of herd protection to those not 
receiving antibiotics. Children typically have a higher prev-
alence of clinically active trachoma than adults, as well as a 
higher prevalence of chlamydial infection [2]. Where moni-
tored, the duration of infection is longer and the load of chla-
mydia is higher in children than adults [24–27]. Mathematical 
models have suggested that children may form a core group 
of trachoma transmission [3]; that is, if transmission were to 
be curtailed in children, then infection would not persist in 
the rest of the community. These models hypothesized that 
that elimination would depend on a trade-off between fre-
quency of treatment and ages covered, and would need to 
be tailored to endemicity. Specifically, models suggested that 
biannual treatment of children aged <12 years should eventu-
ally eliminate infection in moderately infected areas such as 
Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram. Forty-eight communities were randomized to either annual mass treatment of the entire 
community or biannual treatment targeted to children aged ≤12 years. No communities were lost to follow-up, and none discontinued the intervention. All communities were 
included in the analyses at 36 months. Abbreviation: CSI, Centre de Santé Intégrées.
Study Arm 0 mo 6 mo 12 mo 18 mo 24 mo 30 mo 36 mo
Annual–children 92.3% 
(90.2%–94.1%)
89.0% 
(86.8%–91.2%)
89.8% 
(87.8%–91.7%)
84.9%
(81.6%–88.1%)
Annual–adults 76.8% 
(72.0%–81.2%)
70.4% 
(66.7%–74.6%)
71.0% 
(65.7%–76.2%)
76.5%
(69.8%–82.5%)
Biannual–children 87.5% 
(84.0%–90.8%)
85.4% 
(82.0%–88.7%)
87.4% 
(84.3%–90.1%)
87.5% 
(83.6%–90.7%)
87.8% 
(85.1%–89.9%)
84.7% 
(81.1%–87.9%)
83.5%
(79.6%–87.1%)
Biannual–adults 0.4% 
(0.2%–0.8%)
0.1% 
(0.0%–0.3%)
0.2% 
(0.1%–0.3%)
2.4%
(0.0%–8.0%)
The values in parentheses are mean (95% CI). 
aChildren: aged 0–12 y; adults: aged ≥15 y.
Table 1. Baseline Characteristics of Children and Adults in 48 Communities
Characteristic
Mean (95% CI)
Annually Treated 
(24 Communities)
Biannually Treated 
(24 Communities)
Children per community (aged 0–5 y) 156 (108–204) 144 (117–171)
 Age of children, y 2.6 (2.6–2.7) 2.7 (2.6–2.7)
 Proportion female, % 51.2 (49.6–52.8) 49.4 (47.4–51.3)
 Prevalence of trachoma (TF), % 27.7 (21.2–34.2) 24.3 (19.1–29.5)
 Prevalence of trachoma (TI), % 8.3 (5.2–11.5) 7.6 (5.1–10.1)
Adults per community (aged ≥15 y) 249 (173–325) 228 (183–274)
 Age of adults, y 34.5 (33.7–35.2) 33.7 (32.9–34.4)
 Proportion female, % 53.7 (52.6–54.9) 51.9 (50.8–52.9)
 Prevalence of trachoma (TF), % 0.4 (.1–.9) 1.3 (.4–2.8)
 Prevalence of trachoma (TI), % 0.1 (.0–.3) 0.2 (.0–.7)
Abbreviations: CI, confidence interval; TF, trachomatous inflammation–follicular; TI, trachoma-
tous inflammation–intense per the World Health Organization Simplified Grading System [16].
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Niger [3]. A cluster-randomized trial in Nepal found annual 
mass treatment of children aged <10 years to be as success-
ful as treatment targeted to all clinically active children and 
their households [28]. In higher-prevalence Nepali commu-
nities, mass treatment of children was more cost-effective 
[11]. A previous cluster-randomized trial in Ethiopia found 
that quarterly treatment of children under the age of 10 years 
approximately halved the prevalence of infection in untreated 
adults at 1  year, suggesting a short-term form of herd pro-
tection [29]. Here, we distributed antibiotics biannually to 
children aged ≤12 years. Thus results would not necessarily 
apply were treatment given less frequently or to a smaller age 
group [3].
This cluster-randomized trial had several limitations. 
The primary outcome was a sample of children and adults. 
While this sample allows us to make inferences about the 
entire adult population, an estimated 0% prevalence does 
not ensure that infection was in fact eliminated in that age 
group. A  newer generation of PCR-based chlamydia tests 
may be more sensitive than the Roche-Amplicor test used in 
Figure 2. Estimated prevalence of ocular chlamydial infection in children aged ≤5 years over time. Each of 24 communities was monitored biannually (gray curves), with the 
mean (black curve). Annual treatments (arrows) were offered to all members of the community (A); biannual treatment (arrows) was offered only to children aged ≤12 years (B).
Table 2. Antibiotic Coverage in Children and Adultsa
Study Arm 0 mo 6 mo 12 mo 18 mo 24 mo 30 mo 36 mo
Annual–children 92.3% 
(90.2%–94.1%)
89.0% 
(86.8%–91.2%)
89.8% 
(87.8%–91.7%)
84.9%
(81.6%–88.1%)
Annual–adults 76.8% 
(72.0%–81.2%)
70.4% 
(66.7%–74.6%)
71.0% 
(65.7%–76.2%)
76.5%
(69.8%–82.5%)
Biannual–children 87.5% 
(84.0%–90.8%)
85.4% 
(82.0%–88.7%)
87.4% 
(84.3%–90.1%)
87.5% 
(83.6%–90.7%)
87.8% 
(85.1%–89.9%)
84.7% 
(81.1%–87.9%)
83.5%
(79.6%–87.1%)
Biannual–adults 0.4% 
(0.2%–0.8%)
0.1% 
(0.0%–0.3%)
0.2% 
(0.1%–0.3%)
2.4%
(0.0%–8.0%)
The values in parentheses are mean (95% CI). 
aChildren: aged 0–12 y; adults: aged ≥15 y.
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Figure 4. Clinical trachoma activity (follicular trachoma) in children aged ≤5 years over time. Each of 24 communities was monitored biannually (gray curves), with the mean 
(black curve). Annual treatments (arrows) were offered to all members of the community (A); biannual treatment (arrows) was offered only to children aged ≤12 years (B).
Figure 3. Estimated prevalence of ocular chlamydial infection in adults aged ≥15 years over time. Each of 24 communities was monitored biannually (gray curves), with the 
mean (black curve). Annual treatments (arrows) were offered to all members of the community (A); biannual treatment (arrows) was offered only to children aged ≤12 years (B).
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this study [30]. Migration into these communities did occur, 
likely from regions that had not just received antibiotics—
ideally, neighboring areas would be enrolled in similar mass 
treatment programs. Only longer-term and more complete 
follow-up would be able to ensure that complete elimination 
could be achieved with either of these distribution strategies. 
We have not demonstrated here that treating children bian-
nually would be more cost-effective than treating all ages 
annually.
Trachoma control programs have demonstrated remarkable 
success in reducing the trachoma burden worldwide, in large 
part due to mass oral azithromycin distributions. More than 
50 million doses of oral azithromycin per year are now dis-
tributed to trachoma-endemic areas. However, distributions 
are expensive and attaining high treatment coverage in adults 
is difficult. In this community-randomized trial in Niger, the 
prevalence of infection in adults was low at baseline, and even 
lower after repeated treatment of children alone. In similar 
settings, treatment of adults may not be necessary, as compa-
rable results can be obtained by focusing on treatment of only 
children.
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